Evofem Biosciences Announces Issuance Of US Patent No. 11,992,472 Covering Composition And Methods For Contraception With Phexxi Vaginal Gel
Portfolio Pulse from Benzinga Newsdesk
Evofem Biosciences has announced the issuance of U.S. Patent No. 11,992,472, which covers the composition and methods for contraception with Phexxi Vaginal Gel. This is the fifth patent for Phexxi in the United States, further strengthening Evofem's intellectual property portfolio.
June 11, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evofem Biosciences has been granted U.S. Patent No. 11,992,472 for its Phexxi Vaginal Gel, enhancing its intellectual property portfolio and potentially increasing its market competitiveness.
The issuance of a new patent for Phexxi Vaginal Gel enhances Evofem's intellectual property portfolio, which could improve its market position and investor confidence. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100